Physician profile
Daniel M Daly
NPI 1720161391
$2,164.20
in general payments reported to CMS, 2019-2025
20 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.15 · 2020: $464 · 2022: $27.07 · 2023: $221 · 2024: $224 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.94 |
| Education | $531.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $716.28 | 2023-2025 | |
| Musculoskeletal Transplant Foundation INC. | $463.90 | 2020 | |
| Urgo Medical North America, LLC | $132.05 | 2023-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgoclean Ag, Urgok2 |
| Smith+Nephew, INC. | $127.21 | 2023-2024 | Oasis, Renasys Go V2 Home, Grafix Pl |
| Merck Sharp & Dohme LLC | $115.11 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Ethicon US, LLC | $102.49 | 2023-2025 | Vistaseal, Ethicon, Stratafix |
| Vertex Pharmaceuticals Incorporated | $102.27 | 2025 | |
| Tela Bio, INC. | $69.52 | 2024 | Ovitex 2s |
| Acera Surgical, INC. | $55.68 | 2024 | Restrata Wound Matrix |
| Portola Pharmaceuticals, LLC | $51.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.11 | 2025 | Gattex |
| Innovation Technologies INC | $30.61 | 2024 | Irrisept |
| Baxter Healthcare | $27.07 | 2022 | |
| Kci USA, INC. | $21.75 | 2023 | Activ.A.C. |
| Teleflex LLC | $20.19 | 2025 | Quikclot |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $18.30 | 2024 | Integra, Surgimend, Omnigraft |
| Heron Therapeutics, INC. | $17.86 | 2025 | Zynrelef |
| Boston Scientific Corporation | $16.17 | 2025 | Spyglass Discover |
| Ossur Americas, INC. | $14.48 | 2025 | |
| Tei Biosciences INC | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.